A hemolytic assay for clinical investigation of human C2.
The heat lability of early acting components of human complement was studied in detail. Kinetic disappearance of individual components was monitored by hemolytic assay. C2 and factor B were the most heat labile components. We took advantage of the difference in heat stability between C2 and C1 to develop a hemolytic assay for human C2.
D000818:Animals; D003167:Complement Activation; D003175:Complement C2 / Q000032:analysis / Q000172:deficiency*; D004306:Dose-Response Relationship, Immunologic; D006168:Guinea Pigs; D006461:Hemolysis; D006801:Humans; D007700:Kinetics; D013696:Temperature
D003175:Complement C2